A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

Study Identifier
M17-381
CT.gov Identifier
NCT05268068
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Healthy Volunteer
    • Study Drug
  • Risankizumab
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 45 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    \- Body Mass Index (BMI) is \>= 19.0 to \<= 26.0 kg/m2 after rounding to the nearest tenth. BMI is calculated as weight in kg divided by the square of height measured in meters.
    Exclusion Criteria:
    \- Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.

    Protocol Summary

    The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.

    Study Locations

    Location
    Status
    Location
    Shanghai Xuhui Central Hospital /ID# 212830
    Shanghai, Shanghai Municipality, China, 200031
    Status
    Not applicable